Armis Biopharma

Armis Biopharma focuses on non-systemic products intended to protect against resistant pathogens and chemical and biological warfare agents, treat skin infections, and improve wound healing.

FORT COLLINS, CO (July 1, 2024) – Armis Biopharma, Inc. announced today that it has appointed Michael J. Voss as CEO, replacing Ted Ziemann who is retiring after 6 years at the helm. Mr. Ziemann will continue to serve as Chairman of the Armis Biopharma Board of Directors.

A professional engineer and lighting designer, Mr. Ruud is nationally recognized for his expertise in the lighting industry. Mr. Ruud founded Ruud Lighting, Inc. in December of 1982 and served as its Chairman and Chief Executive Officer.

Alan Smith, PhD has over 35 years of executive management experience in research and development, operations, manufacturing, and quality roles in industry. He has served on the Board of Directors since it was formed in 1998.

Ruud holds an executive master’s in business administration degree from Loyola University and received his Bachelor of Science degree in computer science and mathematics from Pepperdine University.

The company aims to reduce the number and severity of infections that cause human suffering and death by creating and developing novel, targeted antimicrobial therapies.

Armis Biopharma's patented Veriox Technology platform is an antimicrobial/antitoxin platform. The company aims to reduce the number and severity of infections that cause human suffering and death by creating and developing novel, targeted antimicrobial therapies.